HUMANIZED ANTIBODIES TO LIV-1 AND USE OF SAME TO TREAT CANCER

(19)

(11)

EP 3 461 847 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 A1)

(48)	Corrigendum issued on:
	14.04.2021 Bulletin 2021/15

(43)	Date of publication:
	03.04.2019 Bulletin 2019/14

(21)	Application number: 18204152.5

(22)	Date of filing: 06.12.2011

(51)

International Patent Classification (IPC):

C07K 16/28^(2006.01)
A61K 47/68^(2017.01)

A61K 39/395^(2006.01)
A61P 35/00^(2006.01)

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

06.12.2010 US 42029110 P
25.02.2011 US 201161446990 P

(60)	Divisional application:
	20189823.6 / 3786185

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	16200557.3 / 3156420
	11847198.6 / 2648752

(71)	Applicant: Seagen Inc.
	Bothell, WA 98021 (US)

(72)	Inventors:
	SMITH, Maria Leia Seattle WA 98133 (US) SUSSMAN, Django Bothell, WA 98021 (US) ARTHUR, William Bothell, WA 98021 (US) NESTEROVA, Albina Bothell, WA 98021 (US)

(74)	Representative: J A Kemp LLP
	14 South Square Gray's Inn London WC1R 5JJ London WC1R 5JJ (GB)


	Remarks:
	This application was filed on 02.11.2018 as a divisional application to the application mentioned under INID code 62.

(54)	HUMANIZED ANTIBODIES TO LIV-1 AND USE OF SAME TO TREAT CANCER

(57) The invention provides humanized antibodies that specifically bind to LIV-1. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting LIV-1.